Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Oct;22(10):925-933.
doi: 10.1016/S1474-4422(23)00271-5. Epub 2023 Aug 28.

The Neurological Pupil index for outcome prognostication in people with acute brain injury (ORANGE): a prospective, observational, multicentre cohort study

Collaborators, Affiliations
Observational Study

The Neurological Pupil index for outcome prognostication in people with acute brain injury (ORANGE): a prospective, observational, multicentre cohort study

Mauro Oddo et al. Lancet Neurol. 2023 Oct.

Abstract

Background: Improving the prognostication of acute brain injury is a key element of critical care. Standard assessment includes pupillary light reactivity testing with a hand-held light source, but findings are interpreted subjectively; automated pupillometry might be more precise and reproducible. We aimed to assess the association of the Neurological Pupil index (NPi)-a quantitative measure of pupillary reactivity computed by automated pupillometry-with outcomes of patients with severe non-anoxic acute brain injury.

Methods: ORANGE is a multicentre, prospective, observational cohort study at 13 hospitals in eight countries in Europe and North America. Patients admitted to the intensive care unit after traumatic brain injury, aneurysmal subarachnoid haemorrhage, or intracerebral haemorrhage were eligible for the study. Patients underwent automated infrared pupillometry assessment every 4 h during the first 7 days after admission to compute NPi, with values ranging from 0 to 5 (with abnormal NPi being <3). The co-primary outcomes of the study were neurological outcome (assessed with the extended Glasgow Outcome Scale [GOSE]) and mortality at 6 months. We used logistic regression to model the association between NPi and poor neurological outcome (GOSE ≤4) at 6 months and Cox regression to model the relation of NPi with 6-month mortality. This study is registered with ClinicalTrials.gov, NCT04490005.

Findings: Between Nov 1, 2020, and May 3, 2022, 514 patients (224 with traumatic brain injury, 139 with aneurysmal subarachnoid haemorrhage, and 151 with intracerebral haemorrhage) were enrolled. The median age of patients was 61 years (IQR 46-71), and the median Glasgow Coma Scale score on admission was 8 (5-11). 40 071 NPi measurements were taken (median 40 per patient [20-50]). The 6-month outcome was assessed in 497 (97%) patients, of whom 160 (32%) patients died, and 241 (47%) patients had at least one recording of abnormal NPi, which was associated with poor neurological outcome (for each 10% increase in the frequency of abnormal NPi, adjusted odds ratio 1·42 [95% CI 1·27-1·64]; p<0·0001) and in-hospital mortality (adjusted hazard ratio 5·58 [95% CI 3·92-7·95]; p<0·0001).

Interpretation: NPi has clinically and statistically significant prognostic value for neurological outcome and mortality after acute brain injury. Simple, automatic, repeat automated pupillometry assessment could improve the continuous monitoring of disease progression and the dynamics of outcome prediction at the bedside.

Funding: NeurOptics.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests GC reports institutional research grants from Integra and NeurOptics; and received personal fees as a speakers’ bureau member and advisory board member from Integra, NeurOptics, Biogen, Idorsia, and Invex Therapeutics, all outside the submitted work; and is the Editor-in-Chief of Intensive Care Medicine. FST received consulting and lecture fees from NeurOptics; and received personal fees as an Advisory Board Member from NeurOptics, all outside the submitted work. MO received fee payments for consultancy roles for NeurOptics and honoraria for lectures by NeurOptics; received personal fees as an advisory board member from NeurOptics, all unrelated to the submitted work; and received institutional grants from the Swiss National Science Foundation. JIS reported personal fees as a member of the Clinical Endpoint Committee for the REACT Study funded by Idorsia; is member of the data safety and monitoring board for the INTREPID study; is a member of the board of directors of the Neurocritical Care Foundation and the Neurocritical Care Society; and is member of the editorial board of Stroke. NB-H received honoraria for lectures from ORION Pharma. ABO received honoraria for educational events from BD, support for attending meetings from Pfizer, and received equipment from NeurOptics. PB received honoraria for lectures from LFB Company and equipment from NeurOptics. RMC received institutional grants from the National Institutes of Health (National Institute of Child Health and Human Development; Fogarty International Centre). SG participated as a data safety and monitoring board member at Division of Cell Matrix Biology and Regenerative Medicine, University of Manchester, without payment. All other authors declare no competing interests.

Comment in

Similar articles

Cited by

Publication types

Associated data